Hot Pursuit     18-Jun-24
Cipla hits record high as UK arm plans to invest additional 3 mln euro in Ethris
The pharma major announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) will invest an additional EUR 3 million in Ethris GmbH, a global leader in delivering mRNAs directly to the respiratory system.

This additional investment through a convertible loan will accelerate Cipla’s participation in the messenger RiboNucleic Acid (mRNA) space.

Earlier, Cipla had invested EUR 15 million in Ethris in 2022. This additional investment reaffirms Cipla’s confidence in Ethris’s proprietary mRNA platform and its potential for patients in emerging markets.

Together, Cipla and Ethris are working towards a long-term strategic partnership to fast-track innovative mRNA-based treatments, said the firm.

During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

Umang Vohra, managing director (MD) & global chief executive officer (CEO), Cipla, said, “At Cipla, we strive to dial-up our focus and investment towards innovative modalities and bring new age therapies to emerging countries, including India. The follow-on investment in Ethris will help get cutting-edge healthcare solutions like mRNA-based therapies to the Global South.

Dr. Carsten Rudolph, CEO, Ethris, added, “The additional investment by Cipla further validates the broad potential of our platform and Ethris’ innovative approaches to developing respiratory RNA-based medicines. We deeply value this ongoing relationship to bring effective solutions to developing countries. The capital will enable us to continue advancing our pipeline and we look forward to providing an update on our lead program in the near term.”

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The pharma company reported 79% jump in consolidated net profit to Rs 939.04 crore on 10% increase in revenue from operations to Rs 6,163 core in Q4 FY24 over Q4 FY23.

The scrip hit an all time high of Rs 1,576.45 in today’s intraday session.

Previous News
  USFDA classifies inspection of Cipla's Kurkumbh unit as Voluntary Action Indicated
 ( Corporate News - 13-Jul-24   12:02 )
  Cipla allots 35,106 equity shares under ESOP
 ( Corporate News - 05-Jul-24   11:02 )
  Cipla to conduct board meeting
 ( Corporate News - 05-Jul-24   10:23 )
  Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
 ( Corporate News - 28-Jun-24   19:23 )
  Cipla Ltd eases for fifth straight session
 ( Hot Pursuit - 25-Jun-24   13:35 )
  USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'
 ( Corporate News - 25-Jun-24   12:12 )
  Cipla gets VAI classification from USFDA for Patalganga facility
 ( Hot Pursuit - 25-Jun-24   11:34 )
  Cipla slides as Goa facility gets 6 USFDA observations
 ( Hot Pursuit - 24-Jun-24   09:47 )
  Cipla Goa facility gets 6 USFDA observations
 ( Hot Pursuit - 22-Jun-24   16:22 )
  Cipla's Goa unit completes USFDA inspection
 ( Corporate News - 22-Jun-24   11:47 )
  Cipla to invest additional EUR 3 million in Ethris GmbH
 ( Corporate News - 18-Jun-24   17:19 )
Other Stories
  JSW Energy PAT soars 80% YoY to Rs 522 crore in Q1 FY25
  20-Jul-24   17:15
  Yes Bank Q1 PAT climbs 47% YoY to Rs 502 crore
  20-Jul-24   16:46
  Patanjali Foods Q1 PAT soars 3-fold to Rs 263 cr
  20-Jul-24   16:08
  Nippon Life Q1 PAT surges 40% YoY to Rs 332 cr
  20-Jul-24   15:44
  HDFC Bank Q1 PAT grows 35% YoY to Rs 16,175 crore
  20-Jul-24   15:31
  Kotak Mahindra Bank Q1 PAT zooms 81% YoY to Rs 6,250 cr
  20-Jul-24   15:13
  JSW Steel Q1 PAT drops 64% YoY to Rs 867 crore
  20-Jul-24   13:39
  ICICI Lombard Q1 PAT climbs 49% YoY to Rs 580 cr
  20-Jul-24   12:14
  Oberoi Realty Q1 PAT soars 82% YoY to Rs 584 cr
  20-Jul-24   11:16
  RIL PAT slides 4% YoY to Rs 17,448 crore in Q1 FY25
  20-Jul-24   10:33
Back Top